Butler Javed, Forman Daniel E, Abraham William T, Gottlieb Stephen S, Loh Evan, Massie Barry M, O'Connor Christopher M, Rich Michael W, Stevenson Lynne Warner, Wang Yongfei, Young James B, Krumholz Harlan M
Vanderbilt University, Nashville, Tenn, USA.
Am Heart J. 2004 Feb;147(2):331-8. doi: 10.1016/j.ahj.2003.08.012.
Among patients who are hospitalized with heart failure (HF), worsening renal function (WRF) is associated with worse outcomes. Whether treatment for HF contributes to WRF is unknown. In this study, we sought to assess whether acute treatment for patients who were hospitalized with HF contributes to WRF.
Data were collected in a nested case-control study on 382 subjects who were hospitalized with HF (191 patients with WRF, defined as a rise in serum creatinine level >26.5 micromol/L [0.3 mg/dL], and 191 control subjects). The association of medications, fluid intake/output, and weight with WRF was assessed.
Calcium channel blocker (CCB) use and loop diuretic doses were higher in patients on the day before WRF (25% vs 10% for CCB; 199 +/- 195 mg vs 143 +/- 119 mg for loop diuretics; both P <.05). There were no significant differences in the fluid intake/output or weight changes in the 2 groups. Angiotensin-converting enzyme (ACE) inhibitor use was not associated with WRF. Other predictors of WRF included elevated creatinine level at admission, uncontrolled hypertension, and history of HF or diabetes mellitus. Higher hematocrit levels were associated with a lower risk. Vasodilator use was higher among patients on the day before WRF (46% vs 35%, P <.05), but was not an independent predictor in the multivariable analysis.
Several medical strategies, including the use of CCBs and a higher dose of loop diuretics, but not ACE inhibitors, were associated with a higher risk of WRF. Although assessment of inhospital diuresis was limited, WRF could not be explained by greater fluid loss in these patients. Determining whether these interventions are responsible for WRF or are markers of higher risk requires further investigation.
在因心力衰竭(HF)住院的患者中,肾功能恶化(WRF)与更差的预后相关。心力衰竭治疗是否会导致肾功能恶化尚不清楚。在本研究中,我们试图评估急性治疗对因心力衰竭住院患者的肾功能恶化是否有影响。
在一项巢式病例对照研究中收集了382例因心力衰竭住院患者的数据(191例肾功能恶化患者,定义为血清肌酐水平升高>26.5微摩尔/升[0.3毫克/分升],以及191例对照受试者)。评估了药物、液体出入量和体重与肾功能恶化的关联。
肾功能恶化前一天,患者使用钙通道阻滞剂(CCB)和襻利尿剂的剂量更高(CCB使用情况:25% 对10%;襻利尿剂剂量:199±195毫克对143±119毫克;均P<.05)。两组的液体出入量或体重变化无显著差异。使用血管紧张素转换酶(ACE)抑制剂与肾功能恶化无关。肾功能恶化的其他预测因素包括入院时肌酐水平升高、未控制的高血压以及心力衰竭或糖尿病病史。血细胞比容水平较高与较低风险相关。肾功能恶化前一天患者使用血管扩张剂的比例更高(46%对35%,P<.05),但在多变量分析中不是独立预测因素。
包括使用CCB和更高剂量襻利尿剂但不包括ACE抑制剂在内的几种治疗策略与肾功能恶化风险较高相关。尽管对住院利尿的评估有限,但这些患者肾功能恶化不能用更大的液体丢失来解释。确定这些干预措施是导致肾功能恶化的原因还是更高风险的标志物需要进一步研究。